Market Cap 161.05M
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 671,800
Avg Vol 763,142
Day's Range N/A - N/A
Shares Out 132.01M
Stochastic %K 11%
Beta -0.31
Analysts Sell
Price Target $5.00

Latest News on RAPT

RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 3 months ago

RAPT Therapeutics Announces $150 Million Private Placement


RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 9 months ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus


RAPT Therapeutics Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 11 months ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results


FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials


RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 13, 2023, 3:59 PM EDT - 1 year ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off


RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results


RAPT Therapeutics: Potential Strong Upside Ahead

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead


RAPT Therapeutics Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2022 Financial Results


RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2022 Financial Results